Syntr Health Technologies Announces An Oversubscribed $2.2 Million Seed Round To Accelerate Market Penetration Of Fda-Cleared Syntrfuge System
Syntr Health Technologies Announces An Oversubscribed $2.2 Million Seed Round To Accelerate Market Penetration Of Fda-Cleared Syntrfuge System
08/12/21, 10:19 AM
Location
irvineMoney raised
$2.2 million
Round Type
seed
Syntr Health Technologies, Inc., a medical device company specializing in the processing of autologous adipose tissue, today announced a $2.2 million seed funding round, which includes previous investors, angels and surgeons participating in the round. Proceeds will be used to build out sales for its patented, FDA-cleared SyntrFuge SystemTM, a single-use disposable medical device that uses a patient's own adipose tissue (also known as fat tissue) at the point of care. The implantation of adipose tissue is known to aid in the natural rejuvenation of soft tissue in plastic and reconstructive surgery. Its minimally invasive approach processes the tissue in minutes resulting in a quick and efficient procedure.
Company Info
Location
irvine, california, united states
Additional Info
Irvine, California-based Syntr Health Technologies, Inc. was founded by three engineers and incorporated in 2018, following the successful grant of an NIH Phase I SBIR (Small Business Innovation Research). The company's mission is to assist physicians with a device that accelerates adipose tissue processing at the point of care. Syntr Health Technologies is focused on becoming the market leader in automated adipose tissue processing, reducing recovery times, and improving quality of life. Syntr is headquartered at University Lab Partners, a premier wet lab incubator in the heart of Orange County.